Following Apple's HealthKit and Samsung's SAMI, Google has unveiled Fit, its entrant in the health and fitness data aggregator race, and like Samsung (but unlike Apple), seems to be focusing more on the fitness and less on the connected health angle that's very much a part of HealthKit. And here's Heartbeat's Bill Drummy on why it all matters.

  • Verizon is getting into the telehealth game with Virtual Visits, a platform for urgent care consults via smartphone.
  • Physicians Interactive (now backed by Merck Global Health Innovation Fund) has acquired MedHelp, maker of patient support and education apps. It's an interesting move into the consumer side for PI, which to date has been pretty physician-focused in their product offerings, and may offer validation for companies investing in patient support and surrounding the patient-physician dialogue.
  • PBMs seem to finally getting tough with Pharma, and it's really putting a dent in sales of some major products. An important development in the tug-of-war between payers and pharmas over drug costs.
  • - See more at: http://healthandpharmainsight.tumblr.com/#sthash.xMJOOuER.dpuf
  • Following Apple’s HealthKit and Samsung’s SAMI, Google has unveiled Fit, its entrant in the health and fitness data aggregator race, and like Samsung (but unlike Apple), seems to be focusing more on the fitness and less on the connected health angle that’s very much a part of HealthKit. And here’s Heartbeat’s Bill Drummy on why it all matters.
  • Verizon is getting into the telehealth game with Virtual Visits, a platform for urgent care consults via smartphone.
  • Physicians Interactive (now backed by Merck Global Health Innovation Fund) has acquired MedHelp, maker of patient support and education apps. It’s an interesting move into the consumer side for PI, which to date has been pretty physician-focused in their product offerings, and may offer validation for companies investing in patient support and surrounding the patient-physician dialogue.
  • PBMs seem to finally getting tough with Pharma, and it’s really putting a dent in sales of some major products. An important development in the tug-of-war between payers and pharmas over drug costs.

What drives the therapy selection test market?

View Now